# GLP-1s and the heart: heart rate, blood pressure, SELECT

Source: https://pepvault.app/guides/glp-1s-and-the-heart

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# GLP-1s and the heart: heart rate, blood pressure and the SELECT trial

Reviewed November 2026 15 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

GLP-1s lift resting heart rate 1 to 4 beats a minute and lower blood pressure. The four labels side by side, plus SELECT, SURPASS-CVOT and SUMMIT on the heart.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 15
- **Questions:** 7
- **Compounds:** 2

## The short answer

GLP-1s lower blood pressure, lift resting heart rate by about 1 to 4 beats a minute, and on the bigger question protect the heart. In SELECT, Wegovy cut heart attacks, strokes and heart deaths by 20% in people with heart disease and no diabetes. Wegovy, Ozempic and Mounjaro now carry a heart-protection use on their labels; Zepbound does not yet.

- Heart rate: up 2 to 3 beats a minute on Ozempic, 1 to 4 on Wegovy, 2 to 4 on Mounjaro and 1 to 3 on Zepbound, by each label; only Wegovy's lists it as a warning to monitor.
- Blood pressure: the top number fell 6.2 mmHg on Wegovy 2.4 mg and 6.6 to 7.7 on Zepbound in SURMOUNT-1, against about 1 on placebo.
- SELECT: 6.5% on semaglutide 2.4 mg against 8.0% on placebo had a heart attack, stroke or heart death over about 40 months (hazard ratio 0.80).
- Heart failure: tirzepatide (SUMMIT) and semaglutide (STEP-HFpEF) helped obesity-related heart failure in trials, but as of November 20, 2026 no US label carries a heart-failure use.

Every number checked at its primary source · Nov 20, 2026 · [15 sources](https://pepvault.app/guides/glp-1s-and-the-heart#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Phase 3 double-blind outcome trials behind three FDA heart indications (SUSTAIN-6 and SELECT against placebo for semaglutide, SURPASS-CVOT against dulaglutide for tirzepatide); heart rate and blood pressure from the four labels' trial pools; two phase 3 heart failure trials and a post hoc pool, with no heart-failure indication yet; the pacemaker-receptor finding is from monkey and human tissue samples.

## Do GLP-1s raise your heart rate?

Yes, by a few beats a minute, and every label says so. A GLP-1 (pepvault.app/glossary/glp-1; a drug that copies the gut hormone that slows the stomach and quiets appetite) acts on receptors well beyond the gut: in monkey and human tissue samples, the GLP-1 receptor sits in the cells of the sinoatrial node, the heart's own pacemaker[15](https://pepvault.app/guides/glp-1s-and-the-heart#source-15). Here is each label's figure, as of November 20, 2026:

| Label | Average rise in heart rate | On placebo | What else the label says |
| --- | --- | --- | --- |
| Ozempic (semaglutide 0.5 and 1 mg) | 2 to 3 beats a minute[1](https://pepvault.app/guides/glp-1s-and-the-heart#source-1) | Down 0.3[1](https://pepvault.app/guides/glp-1s-and-the-heart#source-1) | Listed under adverse reactions; QTc (the heart's electrical reset) not prolonged at doses up to 1.5 mg[1](https://pepvault.app/guides/glp-1s-and-the-heart#source-1) |
| Wegovy (semaglutide 2.4 mg) | 1 to 4 at rest, beyond placebo[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2) | The comparison | A warning (section 5.9): a rise of 20 or more beats at any visit in 26% against 16% on placebo; check heart rate at regular intervals[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2) |
| Mounjaro (tirzepatide) | 2 to 4 beats a minute[3](https://pepvault.app/guides/glp-1s-and-the-heart#source-3) | Up 1[3](https://pepvault.app/guides/glp-1s-and-the-heart#source-3) | Fast-pulse episodes (a rise of 15 or more) in 4.6%, 5.9% and 10% at 5, 10 and 15 mg, against 4.3% on placebo; "clinical relevance … uncertain"[3](https://pepvault.app/guides/glp-1s-and-the-heart#source-3) |
| Zepbound (tirzepatide) | 1 to 3 beats a minute[4](https://pepvault.app/guides/glp-1s-and-the-heart#source-4) | No rise[4](https://pepvault.app/guides/glp-1s-and-the-heart#source-4) | Listed under adverse reactions[4](https://pepvault.app/guides/glp-1s-and-the-heart#source-4) |

On Zepbound the rise grows with the dose: at 5 mg the pulse sat 0.5 beats above placebo at 72 weeks, at 10 and 15 mg 2.2 and 2.5 beats above[4](https://pepvault.app/guides/glp-1s-and-the-heart#source-4). And a higher dose does not always mean a bigger rise: in the trial of Wegovy 7.2 mg, resting heart rate rose 0.5 beats against a 0.6 fall on placebo, a gap of 1 beat[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2). No label gives the week the rise starts. Wegovy's is the only one that tells prescribers to stop the drug if a person's resting heart rate stays up[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2).

<!--promo-->

With Apple Health connected, the dose card on PepVault's Today screen shows the day's resting heart rate in its footer, beside sleep, HRV and steps (with Whoop connected, Whoop's recovery line takes that spot). [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-glp-1s-and-the-heart-inline&mt=8)

<!--/promo-->

**Commonly reported:** a resting heart rate a few beats higher. On our reports pages it is a small complaint: a higher resting rate is named in 2 of 41 semaglutide write-ups and 3 of 77 tirzepatide write-ups; one more tirzepatide user names a racing heart, and one a lower resting rate.

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

With Apple Health connected, the dose card on PepVault's Today screen shows the day's resting heart rate in its footer, beside sleep, HRV and steps (with Whoop connected, Whoop's recovery line takes that spot).

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## How much do GLP-1s lower blood pressure?

By about 5 to 8 points on the top number (**systolic** pressure, the push while the heart beats) in the main weight trials against about 1 point on placebo, and 10 on Wegovy 7.2 mg. The two weight-loss labels print the numbers; Ozempic's and Mounjaro's give none[1](https://pepvault.app/guides/glp-1s-and-the-heart#source-1) [3](https://pepvault.app/guides/glp-1s-and-the-heart#source-3).

| Trial on the label | Drug and dose | Systolic change on the drug | On placebo |
| --- | --- | --- | --- |
| Study 2 (STEP 1), adults with obesity, 68 weeks | Wegovy 2.4 mg | -6.2 mmHg[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2) | -1.1[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2) |
| Study 8 (STEP UP), adults with obesity, 72 weeks | Wegovy 7.2 mg | -10.1 mmHg[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2) | -4.8[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2) |
| SELECT, heart disease and no diabetes, 104 weeks | Wegovy 2.4 mg | -3.8 mmHg[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2) | -0.5[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2) |
| SURMOUNT-1, adults with obesity, 72 weeks | Zepbound 5, 10, 15 mg | -6.6, -7.7, -7.4 mmHg[4](https://pepvault.app/guides/glp-1s-and-the-heart#source-4) | -1.0[4](https://pepvault.app/guides/glp-1s-and-the-heart#source-4) |
| SURMOUNT-2, obesity and type 2 diabetes, 72 weeks | Zepbound 10, 15 mg | -5.6, -7.1 mmHg[4](https://pepvault.app/guides/glp-1s-and-the-heart#source-4) | -1.2[4](https://pepvault.app/guides/glp-1s-and-the-heart#source-4) |

From Wegovy's Tables 7, 13 and 17 and Zepbound's cardiometabolic table[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2) [4](https://pepvault.app/guides/glp-1s-and-the-heart#source-4). People in SELECT started at 131 mmHg, and 74% already took an ACE inhibitor or ARB, two common blood-pressure medicines, which leaves less room to fall[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2). Rates from different trials are not a head-to-head comparison.

For a few people the fall goes too far, mostly those on blood-pressure medicine or drying out from vomiting: low blood pressure came in 1.3% on Wegovy against 0.4% on placebo, and 1.6% on Zepbound against 0.1%[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2) [4](https://pepvault.app/guides/glp-1s-and-the-heart#source-4). Our guide to dizziness on a GLP-1 (pepvault.app/guides/dizziness-on-a-glp-1) covers what that feels like and what helps.

## What did the SELECT trial find?

SELECT asked whether semaglutide protects the heart in people who have obesity but not diabetes. It enrolled 17,604 adults aged 45 or older with a BMI of 27 or more and an earlier heart attack, stroke or narrowed leg arteries, and gave half semaglutide 2.4 mg a week and half a placebo (pepvault.app/glossary/placebo; a dummy shot), double-blind, for a mean 39.8 months[5](https://pepvault.app/guides/glp-1s-and-the-heart#source-5). Its main count was **MACE**, major adverse cardiovascular events: a heart death, a heart attack or a stroke.

| Outcome in SELECT | Wegovy 2.4 mg (8,803) | Placebo (8,801) | Hazard ratio |
| --- | --- | --- | --- |
| MACE, the main count | 6.5% | 8.0% | 0.80 |
| Heart attack, fatal or not | 2.8% | 3.8% | 0.72 |
| Stroke, fatal or not | 1.8% | 2.0% | 0.89 |
| Heart death | 2.5% | 3.0% | 0.85 |
| Death from any cause | 4.3% | 5.2% | 0.81 |
| Heart failure hospital stay or urgent visit | 1.1% | 1.4% | 0.79 |

From the Wegovy label's Table 6[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2). A hazard ratio of 0.80 means the event came 20% less often over time. Only the MACE result was confirmed by the trial's testing plan; heart death fell short of confirmation, and the label states that an effect on heart failure has not been established[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2). The SELECT study page (pepvault.app/research/semaglutide-select-2023) has the full design.

On March 8, 2024 the FDA approved Wegovy to reduce the risk of heart attacks, strokes and heart deaths in adults with heart disease and obesity or overweight, calling it the first weight-loss medicine approved to help prevent such events[6](https://pepvault.app/guides/glp-1s-and-the-heart#source-6). The price was the stomach: 16.6% stopped semaglutide for a side effect, against 8.2% on placebo[5](https://pepvault.app/guides/glp-1s-and-the-heart#source-5). Novo Nordisk, which makes semaglutide, funded the trial[5](https://pepvault.app/guides/glp-1s-and-the-heart#source-5).

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)
- [Constipation on Ozempic, Mounjaro or Zepbound: how common, and what helps](https://pepvault.app/guides/constipation-on-a-glp-1)
- [Nausea on Ozempic, Wegovy, Mounjaro or Zepbound: when it peaks and what helps](https://pepvault.app/guides/nausea-on-a-glp-1)
- [Headaches on a GLP-1: how common they were in the trials](https://pepvault.app/guides/headaches-on-a-glp-1)
- [Sulfur burps on Ozempic or Mounjaro: why they happen](https://pepvault.app/guides/sulfur-burps-on-a-glp-1)
- [GLP-1s and the gallbladder: gallstones, and taking one without a gallbladder](https://pepvault.app/guides/glp-1s-and-the-gallbladder)
- [Do GLP-1s cause cancer? The thyroid warning and what the studies show](https://pepvault.app/guides/do-glp-1s-cause-cancer)
- [Retatrutide and cancer: what the warning and the studies say](https://pepvault.app/guides/retatrutide-and-cancer)
- [Retatrutide and muscle loss: what the studies measured](https://pepvault.app/guides/retatrutide-and-muscle)

### Terms on this page

- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Adverse reaction](https://pepvault.app/glossary/adverse-reaction)
- [Double-blind](https://pepvault.app/glossary/double-blind)
- [Post hoc analysis](https://pepvault.app/glossary/post-hoc-analysis)
- [Body mass index (BMI)](https://pepvault.app/glossary/bmi)

## Is the heart benefit just the weight loss?

Not by SELECT's own analysis. A prespecified analysis found the protection the same at every starting weight, and no link between the weight a person lost in the first 20 weeks and their heart risk afterwards; in the authors' words, the protection was "independent of baseline adiposity and weight loss"[7](https://pepvault.app/guides/glp-1s-and-the-heart#source-7). A shrinking waist mattered more: about a third of the benefit (33%) ran through the fall in waist size, and the authors read that as "some mechanisms for benefit beyond adiposity reduction"[7](https://pepvault.app/guides/glp-1s-and-the-heart#source-7). Lower blood pressure is one candidate the trials measure; less inflammation is another, since C-reactive protein, a blood marker of inflammation, fell 43.5% against 7.3% on placebo in STEP-HFpEF[11](https://pepvault.app/guides/glp-1s-and-the-heart#source-11).

## Which GLP-1 labels carry a heart-protection use?

Three of the four, each from its own outcome trial: a study built to count heart attacks, strokes and heart deaths, so it keeps thousands of people on the drug for years.

| Label | Heart use, as of November 20, 2026 | The trial behind it | Result |
| --- | --- | --- | --- |
| Ozempic | Lower MACE in adults with type 2 diabetes and heart disease[1](https://pepvault.app/guides/glp-1s-and-the-heart#source-1) | SUSTAIN-6: 3,297 people, about 2 years, against placebo[1](https://pepvault.app/guides/glp-1s-and-the-heart#source-1) [8](https://pepvault.app/guides/glp-1s-and-the-heart#source-8) | 6.6% against 8.9%, hazard ratio 0.74[1](https://pepvault.app/guides/glp-1s-and-the-heart#source-1) |
| Wegovy (shot and tablets) | Lower MACE in adults with heart disease and obesity or overweight[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2) | SELECT: 17,604 people, no diabetes, against placebo[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2) [5](https://pepvault.app/guides/glp-1s-and-the-heart#source-5) | 6.5% against 8.0%, hazard ratio 0.80[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2) |
| Mounjaro | Lower MACE in adults with type 2 diabetes at high risk of them, added August 2026[3](https://pepvault.app/guides/glp-1s-and-the-heart#source-3) | SURPASS-CVOT: 13,299 people, about 4 years, against dulaglutide (Trulicity)[3](https://pepvault.app/guides/glp-1s-and-the-heart#source-3) [9](https://pepvault.app/guides/glp-1s-and-the-heart#source-9) | 12.1% against 13.0%, hazard ratio 0.92: no worse than dulaglutide, not shown better[3](https://pepvault.app/guides/glp-1s-and-the-heart#source-3) |
| Zepbound | None; its uses are weight and sleep apnea[4](https://pepvault.app/guides/glp-1s-and-the-heart#source-4) | SURMOUNT-MMO, 15,374 people with obesity against placebo; the registry estimates primary completion in October 2027[10](https://pepvault.app/guides/glp-1s-and-the-heart#source-10) | Not yet reported[10](https://pepvault.app/guides/glp-1s-and-the-heart#source-10) |

SURPASS-CVOT is the odd one out because it tested tirzepatide against another GLP-1 that already protects the heart, not against a dummy shot. Fewer people died of any cause on tirzepatide, 8.5% against 10.1%, a result the label marks as outside the trial's error control[3](https://pepvault.app/guides/glp-1s-and-the-heart#source-3). The SUSTAIN-6 study page (pepvault.app/research/semaglutide-sustain-6-2016) has the semaglutide diabetes trial, and our guide to whether GLP-1s are safe long term (pepvault.app/guides/are-glp-1s-safe-long-term) sets these trials beside the other long ones. Each brand's full label is on its page: Ozempic (pepvault.app/drugs/ozempic), Wegovy (pepvault.app/drugs/wegovy), Mounjaro (pepvault.app/drugs/mounjaro) and Zepbound (pepvault.app/drugs/zepbound).

## Do GLP-1s help heart failure?

In one kind, the trials say yes. **HFpEF** (heart failure with preserved ejection fraction) is a stiff heart that pumps a normal share of its blood but fills poorly, leaving people breathless; obesity drives much of it. Two trials tested GLP-1s in exactly those people:

- **SUMMIT (tirzepatide up to 15 mg):** 731 adults with HFpEF and a BMI of 30 or more, followed a median of 104 weeks. A heart death or worsening heart failure came in 9.9% against 15.3% on placebo (hazard ratio 0.62); worsening heart failure alone in 8.0% against 14.2%. Heart deaths were few, 8 against 5, too few to read[13](https://pepvault.app/guides/glp-1s-and-the-heart#source-13).
- **STEP-HFpEF (semaglutide 2.4 mg):** 529 adults, 52 weeks. A 0 to 100 symptom score rose 16.6 points against 8.7, the six-minute walk lengthened 21.5 metres against 1.2, and weight fell 13.3% against 2.6%[11](https://pepvault.app/guides/glp-1s-and-the-heart#source-11).
- **The semaglutide pool (a post hoc analysis):** across SELECT, FLOW and both STEP-HFpEF trials, 3,743 people had HFpEF; a heart death or heart failure event came in 5.4% against 7.5% (hazard ratio 0.69)[12](https://pepvault.app/guides/glp-1s-and-the-heart#source-12).

Neither use is on a US label. On May 1, 2025, Lilly's chief scientific officer told investors it had withdrawn its US application for tirzepatide in HFpEF because the FDA asked for another confirmatory trial, as ConscienHealth reported[14](https://pepvault.app/guides/glp-1s-and-the-heart#source-14); and Wegovy's label still states that an effect on heart failure has not been established[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2). Both companies paid for their trials[11](https://pepvault.app/guides/glp-1s-and-the-heart#source-11) [13](https://pepvault.app/guides/glp-1s-and-the-heart#source-13).

## Who decides whether a GLP-1 is for your heart?

Your prescriber, often with a cardiologist. The labels set the frame: the heart uses are for people who already have heart disease, or type 2 diabetes at high risk, and each sits beside the usual heart medicines rather than replacing them; in SELECT 90% also took a cholesterol-lowering drug and 86% a blood-thinning antiplatelet[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2). Whether a GLP-1 fits, which one, and whether a blood-pressure medicine changes as the weight comes off are the prescriber's calls. Wegovy's Medication Guide adds one routine check: your healthcare provider should check your heart rate while you take it[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2).

<!--promo-->

PepVault's side-effect log records a racing heart or a dizzy spell under the compound you take, with its date, a severity from minimal to very severe and a note, so your prescriber can see when it began. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-glp-1s-and-the-heart-inline&mt=8)

<!--/promo-->

**When to get help** Wegovy's Medication Guide puts it plainly: tell your healthcare provider if your heart races or pounds in your chest and it lasts for several minutes[2](https://pepvault.app/guides/glp-1s-and-the-heart#source-2).

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Ozempic (semaglutide) injection, prescribing information (§1, §6.1 Increases in Heart Rate, §12.2 QTc, §14.2 SUSTAIN 6 and Table 9). Novo Nordisk. DailyMed, SPL version 20, effective June 1, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79)
2. Wegovy (semaglutide) injection and tablets, prescribing information and Medication Guide (§1, §5.9 Heart Rate Increase, §6.1, §14.1 Table 6 and 7, Tables 13 and 17). Novo Nordisk. DailyMed, SPL version 19, effective June 18, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
3. Mounjaro (tirzepatide) injection, prescribing information (§1, Recent Major Changes 08/2026, §6.1 Heart Rate Increase, §14.6 SURPASS-CVOT and Table 10). Eli Lilly and Company. DailyMed, SPL version 40, effective August 27, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0)
4. Zepbound (tirzepatide) injection, prescribing information (§1, §6.1 Heart Rate Increase and Hypotension, §14 cardiometabolic table). Eli Lilly and Company. DailyMed, SPL version 40, effective August 28, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
5. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. [PubMed 37952131](https://pubmed.ncbi.nlm.nih.gov/37952131/)
6. US FDA. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. Press announcement, March 8, 2024. [fda.gov](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or)
7. Deanfield J et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025;406(10516):2257-2268. [PubMed 41138739](https://pubmed.ncbi.nlm.nih.gov/41138739/)
8. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. [PubMed 27633186](https://pubmed.ncbi.nlm.nih.gov/27633186/)
9. Nicholls SJ et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). N Engl J Med. 2025;393(24):2409-2420. [PubMed 41406444](https://pubmed.ncbi.nlm.nih.gov/41406444/)
10. ClinicalTrials.gov. SURMOUNT-MMO: tirzepatide on morbidity and mortality in adults with obesity (NCT05556512). Eli Lilly and Company. Active, not recruiting; 15,374 enrolled; primary completion estimated October 2027. Record updated November 12, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05556512)
11. Kosiborod MN et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity (STEP-HFpEF). N Engl J Med. 2023;389(12):1069-1084. [PubMed 37622681](https://pubmed.ncbi.nlm.nih.gov/37622681/)
12. Kosiborod MN et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949-961. [PubMed 39222642](https://pubmed.ncbi.nlm.nih.gov/39222642/)
13. Packer M et al. Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). N Engl J Med. 2025;392(5):427-437. [PubMed 39555826](https://pubmed.ncbi.nlm.nih.gov/39555826/)
14. ConscienHealth. Lilly withdraws tirzepatide application to FDA for heart failure (reporting Lilly's chief scientific officer at its May 1, 2025 investor call). May 3, 2025. [conscienhealth.org](https://conscienhealth.org/2025/05/03/lilly-withdraws-tirzepatide-application-to-fda-for-heart-failure/)
15. Pyke C et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155(4):1280-1290. [PubMed 24467746](https://pubmed.ncbi.nlm.nih.gov/24467746/)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Do GLP-1s cause cancer? The thyroid warning and what the studies show](https://pepvault.app/guides/do-glp-1s-cause-cancer)

The thyroid warning on Ozempic, Wegovy, Mounjaro and Zepbound comes from rats. What human studies, FDA and EMA found on thyroid, pancreatic and other cancers.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)

## Related guides

- Guide · GLP-1s

  ### [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)

  The longest GLP-1 trials ran 2 to 5.4 years, and heart events and deaths were the same or lower on the drug. The long-term risks, the thyroid warning, cycling.

  Read the guide
- Guide · GLP-1s

  ### [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)

  Dizziness hit 8% on Wegovy vs 4% on placebo, 4-5% on Zepbound vs 2%. How to tell dehydration, falling blood pressure and low blood sugar apart, and what helps.

  Read the guide
- Guide · GLP-1s

  ### [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)

  Ozempic is approved to slow kidney disease after the FLOW trial, yet every GLP-1 label warns of kidney injury from dehydration. Both sides, label by label.

  Read the guide
- Guide · GLP-1s

  ### [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)

  Ozempic, Wegovy, Mounjaro and Zepbound side by side: ingredient, approved use, dose steps, top dose, missed-dose rule and trial weight loss, from each FDA label

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)
- [Constipation on Ozempic, Mounjaro or Zepbound: how common, and what helps](https://pepvault.app/guides/constipation-on-a-glp-1)
- [Nausea on Ozempic, Wegovy, Mounjaro or Zepbound: when it peaks and what helps](https://pepvault.app/guides/nausea-on-a-glp-1)
- [Headaches on a GLP-1: how common they were in the trials](https://pepvault.app/guides/headaches-on-a-glp-1)
- [Sulfur burps on Ozempic or Mounjaro: why they happen](https://pepvault.app/guides/sulfur-burps-on-a-glp-1)
- [GLP-1s and the gallbladder: gallstones, and taking one without a gallbladder](https://pepvault.app/guides/glp-1s-and-the-gallbladder)
- [Do GLP-1s cause cancer? The thyroid warning and what the studies show](https://pepvault.app/guides/do-glp-1s-cause-cancer)
- [Retatrutide and cancer: what the warning and the studies say](https://pepvault.app/guides/retatrutide-and-cancer)
- [Retatrutide and muscle loss: what the studies measured](https://pepvault.app/guides/retatrutide-and-muscle)

### Terms on this page

- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Adverse reaction](https://pepvault.app/glossary/adverse-reaction)
- [Double-blind](https://pepvault.app/glossary/double-blind)
- [Post hoc analysis](https://pepvault.app/glossary/post-hoc-analysis)
- [Body mass index (BMI)](https://pepvault.app/glossary/bmi)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
